Increased detection of ALK resistance mutations has been shown to correlate with the high-risk clinical phenotype associated with the EML4-ALK variant 3 (V3), as confirmed by liquid biopsy analyses in ALK+ NSCLC patients [86]. Here, ALK is linked to non-small cell lung carcinoma.